The present disclosure provides engineered CD47 proteins and uses thereof. Also disclosed are poly nucleotides encoding the engineered CD47 protein, vectors comprising the polynucleotides, cells comprising the engineered proteins and/or the vectors, and compositions comprising the engineered CD47 protein.

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and uses thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and uses thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

The current disclosure provides novel methods and compositions to suppress immunity and are useful for treating autoimmune and inflammatory conditions, and in some circumstances, cancers. Accordingly, aspects of the disclosure relate to a method for treating an inflammatory, autoimmune, autoinflammatory or cancer disease or condition in a subject comprising administering a DUX4 polypeptide or nucleic acid encoding a DUX4 polypeptide to the subject. Further aspects relate to a method for treating a tissue transplant subject, the method comprising administering a DUX4 polypeptide or nucleic acid encoding a DUX4 polypeptide to the subject. The present inventions also relate to universal donor stem cells that overcome immune rejection in cell-based transplantation therapies.

The current disclosure provides novel methods and compositions to suppress immunity and are useful for treating autoimmune and inflammatory conditions, and in some circumstances, cancers. Accordingly, aspects of the disclosure relate to a method for treating an inflammatory, autoimmune, autoinflammatory or cancer disease or condition in a subject comprising administering a DUX4 polypeptide or nucleic acid encoding a DUX4 polypeptide to the subject. Further aspects relate to a method for treating a tissue transplant subject, the method comprising administering a DUX4 polypeptide or nucleic acid encoding a DUX4 polypeptide to the subject. The present inventions also relate to universal donor stem cells that overcome immune rejection in cell-based transplantation therapies.

The present application provides formulations of enhanced antigen presenting cells (enhanced APCs), wherein the formulation comprises: the enhanced APCs comprising an antigen (e.g., a human papillomavirus (HPV) antigen) and one or more of the following: cryopreservation medium, hypothermic preservation medium, and human serum albumin. Also provided herein are methods of producing such formulations and the enhanced APCs.

The present application provides formulations of enhanced antigen presenting cells (enhanced APCs), wherein the formulation comprises: the enhanced APCs comprising an antigen (e.g., a human papillomavirus (HPV) antigen) and one or more of the following: cryopreservation medium, hypothermic preservation medium, and human serum albumin. Also provided herein are methods of producing such formulations and the enhanced APCs.

The present disclosure provides compositions and methods for engineering T cells (e.g., v1 T cells and v2 T cells) with an IL-15 receptor subunit (IL-15R), e.g., by transduction with a viral vector, to restore IL-15 responsiveness. Further provided are populations of engineered T cells and methods of using the same.

The present disclosure provides compositions and methods for engineering T cells (e.g., v1 T cells and v2 T cells) with an IL-15 receptor subunit (IL-15R), e.g., by transduction with a viral vector, to restore IL-15 responsiveness. Further provided are populations of engineered T cells and methods of using the same.

Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or direct CAR expressing cell-mediated immune response in vitro and in vivo.